A New Era for NOACs:

Program Goals

Evidence For NOACs in Patients With NVAF-PCI

PIONEER AF-PCI Study Design

PIONEER AF-PCI Clinically Significant Bleeding

Assessing Competing Risks

RE-DUAL-PCI Trial Design

RE-DUAL-PCI Primary Endpoint: ISTH Major or CRNM Bleeding Event

RE-DUAL-PCI: Efficacy End Points

Choosing The Right Dose

AUGUSTUS Trial Study Design

COMPASS Trial Study Design

COMPASS Trial Baseline Characteristics

COMPASS -- Primary Endpoint* Rivaroxaban Plus Aspirin vs Aspirin Alone

COMPASS Trial Efficacy Outcomes

COMPASS Trial Major Bleeding

COMPASS Trial Net Clinical Benefit

COMPASS Trial: Cumulative Incidence of Primary Efficacy Outcome

COMPASS Trial Subgroup Analysis

NOAC Trials in Process

COMMANDER HF Rivaroxaban in HF

NOAC Trials in Process: Unresolved Issues in Established Indications

NOAC Trials in Process: Potential New Indications

Concluding Remarks

Abbreviations

Abbreviations (cont)